MARKETS
Markets

VivoSim Labs Announces First Commercial Sales In China For Its NAMkind Testing Services

Jul 21, 2026 · 08:08 AM ET· updated 4h ago

, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced its first commercial sales in China, opening a

Share
Why It Matters

VivoSim Labs just made its first sale of testing services in China, which is a big new market for the company. This shows the company is growing into new places, so watch whether they keep landing more customers there.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.